How much revenue does Immunotech Biopharm make?

Immunotech Biopharm reported 0 CNY in revenue for fiscal year 2025.

What companies are similar to Immunotech Biopharm?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Sunho Biologics, Inc. (2898.HK), 3D Medicines (1244.HK), Wuhan YZY Biopharma Co., Ltd. (2496.HK).

Immunotech Biopharm Ltd (6978.HK) Stock

About Immunotech Biopharm Ltd

Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People's Republic of China. The company's core product is EAL, a multi-target cellular immunotherapy product that has completed Phase III clinical trials for the prevention of postsurgical recur...

At a glance

Immunotech Biopharm reported revenue of 0 CNY for fiscal year 2025, and net income of -230.79 million CNY.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.